Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05638737 | A Study in Participants With Non-cirrhotic NASH With Fibrosis | PHASE2 | COMPLETED | 112 | — | — | Oct 26, 2022 | Apr 4, 2024 | Jul 9, 2025 | 65 | United States, Argentina +7 |
ALT at 12 weeks relative to baseline. ALT is measured in Units per litre (U/L)
| Arm | Type | Description |
|---|---|---|
| AZD4831 | EXPERIMENTAL | AZD4831 |
| Placebo | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| AZD4831 | DRUG | AZD4831 |
| Placebo | OTHER | Placebo |
Inclusion Criteria: 1. Participant must be ≥ 18 to ≤ 75 years of age at the time of signing the informed consent. 2. Histological confirmed NASH per Clinical Research Network (CRN) criteria as diagnosed by liver biopsy (within 12 months prior screening, participants without historical biopsy should...